Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Encouraging Results Of AXON's Tau Vaccine Advance Alzheimer's Therapy in 'Biospace.com', BUSINESS WIRE, 7/23/2015

Excerpts:
"Biotech firm AXON Neuroscience has presented encouraging results from a Phase 1 study with a vaccine designed to target diseased tau proteins in Alzheimer’s patients. AXON is not only the first company to successfully complete a Phase 1 study with an active tau vaccine, but the first to show excellent safety profile with an active treatment in Alzheimer’s research.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150723005117/en/

"According to coordinating investigator Professor Reinhold Schmidt from Medical University Graz, who presented the results at the at the Alzheimer’s Association International Conference 2015 (AAIC) in Washington D.C., the vaccine is safe and well tolerated in all assessed parameters. Additionally, the treatment induced robust immune response in vast majority of the study participants and the average cognition of patients remained stable over 6 months. These promising results lead to big expectations in the upcoming Phase II study.

TAU AS A DRIVING FORCE IN ALZHEIMER’S

The researchers at AXON Neuroscience have extensively worked on tau hypothesis for more than 25 years. Through the years, they have proven in various experiments that tau is the driving force in Alzheimer’s disease. This was also recently confirmed by the researchers at Mayo Clinic, USA, who have found by examining more than 3,600 postmortem brains that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer's disease."

News Release at:
http://www.biospace.com/News/encouraging-results-of-axons-tau-vaccine-advance/385338